Stock Price Movement and Market Context
On 2 Feb 2026, Lyka Labs Ltd opened with a gap down of -2.07%, continuing its downward trajectory to hit an intraday low of Rs.70, representing a day decline of -2.76%. The stock traded within a narrow range of just Rs.0.5, reflecting subdued volatility but persistent selling pressure. This performance notably underperformed the Pharmaceuticals & Biotechnology sector by -1.62% on the same day.
Lyka Labs is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend. This technical positioning underscores the stock’s weak momentum relative to its historical price levels.
Meanwhile, the broader market has also shown signs of caution. The Sensex opened lower by 167.26 points and was trading at 80,542.45, down -0.22%. Several indices, including the S&P Bse FMCG and NIFTY FMCG, also hit new 52-week lows on the same day, indicating a cautious market environment.
Long-Term Price Performance and Valuation
Over the past year, Lyka Labs Ltd’s stock price has declined by -50.88%, a stark contrast to the Sensex’s positive return of 3.86% during the same period. The stock’s 52-week high was Rs.155.35, highlighting the extent of the recent correction. This underperformance extends beyond the last year, with the stock lagging behind the BSE500 index over the last three years, one year, and three months.
The company’s valuation metrics reflect elevated risk. Lyka Labs is classified as a high debt company, with an average debt-to-equity ratio of 2.98 times, which is considerably above typical sector norms. This leverage level contributes to the stock’s classification as a Strong Sell, with a Mojo Score of 3.0 and a recent downgrade from Sell to Strong Sell on 12 Jan 2026.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Financial Performance and Profitability Trends
Lyka Labs’ recent quarterly results reveal significant declines in key financial metrics. For the quarter ended December 2025, the company reported a Profit Before Tax (PBT) excluding other income of Rs. -1.32 crore, a steep fall of -148.18% compared to the previous period. The Profit After Tax (PAT) stood at Rs.0.00 crore, marking a 100% decline. Net sales for the quarter were at their lowest level, Rs.30.73 crore, indicating subdued revenue generation.
The company’s operating profit has deteriorated sharply over the last five years, with an annualised decline rate of -170.47%. This negative growth trajectory has contributed to the stock’s weak long-term fundamentals and heightened risk profile.
Profitability has also been volatile and negative in recent periods, with operating profits falling by -116% over the past year. This has compounded the stock’s underperformance relative to its historical valuations and sector peers.
Shareholding and Corporate Structure
The majority shareholding in Lyka Labs Ltd remains with the promoters, indicating concentrated ownership. This structure can influence strategic decisions and capital allocation, particularly in a challenging financial environment.
Why settle for Lyka Labs Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Summary of Key Concerns
Lyka Labs Ltd’s stock has been under pressure due to a combination of weak financial results, high leverage, and sustained declines in profitability and sales. The stock’s trading below all major moving averages and its recent downgrade to a Strong Sell grade reflect these challenges. The company’s negative operating profit trends and subdued revenue growth have contributed to its underperformance relative to the broader market and sector indices.
Despite the broader market showing some weakness, Lyka Labs’ decline has been more pronounced, with a 52-week low of Rs.70 reached today. This level is less than half of its 52-week high of Rs.155.35, underscoring the extent of the correction over the past year.
Investors and market participants will continue to monitor the company’s financial disclosures and market movements closely as the stock remains in a challenging phase.
Unlock special upgrade rates for a limited period. Start Saving Now →
